Home Ingredients Levagen+® (PEA — Palmitoylethanolamide — Gencor)
Anti-InflammatoryCognitiveSleep

Levagen+® (PEA — Palmitoylethanolamide — Gencor)

Evidence Level
Strong
3 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Levagen+® is the branded bioavailable palmitoylethanolamide (PEA) from Gencor (Austin, TX) — addressing the major issue with standard PEA: poor bioavailability of the hydrophobic compound. Levagen+® combines Gencor's PEA with LipiSperse® dispersion technology developed by Pharmako Biotechnologies (Australia, Gencor's sister/partner company) to enhance water dispersibility and bioavailability. A published pharmacokinetic study documented 1.75x absorption increase over standard PEA — meaningful but more modest than typical 'enhanced bioavailability' marketing implies. Clinical trials specifically using Levagen+® document benefits in pain, inflammation, sleep, and cognitive applications. The enhanced absorption may enable somewhat lower effective doses than standard PEA protocols, though the 1.75x absorption advantage doesn't translate to a proportional dose reduction. The honest framing: Levagen+® offers a documented bioavailability advantage over standard PEA through measured absorption-enhancing technology; the brand premium reflects this measurable improvement plus quality control; for users specifically seeking bioavailable PEA, Levagen+® provides clinically validated formulation.

Studied Dose Standard dose: 300-600 mg/day Levagen+® — substantially lower than typical PEA protocols due to enhanced bioavailability. Sleep applications: 350 mg before bedtime. Pain applications: 300 mg twice daily. Long-term safety established through clinical trial use.
Active Compound Levagen+® palmitoylethanolamide (PEA) from Gencor (Austin, TX), combined with LipiSperse® dispersion technology from Pharmako Biotechnologies (Australia). Documented 1.75x absorption increase vs standard PEA.

Benefits

Enhanced bioavailability over standard PEA

Levagen+® combines Gencor's PEA with LipiSperse® dispersion technology from Pharmako Biotechnologies. A published pharmacokinetic study documented 1.75x increased plasma PEA concentration vs standard PEA — meaningful but more modest than what 'enhanced bioavailability' marketing language sometimes implies.

Supported by Trial 2, Trial 1

Pain reduction at lower doses

Clinical trials using Levagen+® document pain reduction at 300-600 mg/day. While typical PEA pain protocols use 1,200 mg/day, the 1.75x bioavailability advantage doesn't translate to a 4x dose reduction — the lower effective doses in clinical trials may also reflect study design choices and different patient populations.

Supported by Trial 1

Sleep quality improvement

Levagen+® clinical trials specifically document sleep quality improvements when taken before bedtime. The sleep application is well-suited to the enhanced bioavailability format and represents an expanding evidence area for PEA.

Supported by Trial 2

Cognitive function support

Emerging Levagen+® research targets cognitive function support through PEA's anti-neuroinflammatory effects. Effect sizes are modest; useful as cognitive support adjunct rather than primary nootropic.

Supported by Trial 3

Anti-inflammatory effects

Like standard PEA, Levagen+® modulates PPAR-alpha and reduces inflammatory cytokines. The mechanism is preserved with enhanced absorption supporting more reliable clinical effects.

Supported by Trial 2, Trial 3

Consumer-friendly dose format

Lower effective doses (300-600 mg) enable consumer-friendly capsule formats versus larger PEA protocols requiring multiple capsules at higher doses. Practical advantage for adherence.

Supported by Trial 1

Mechanism of action

1

LipiSperse® dispersion technology

LipiSperse® is developed and owned by Pharmako Biotechnologies (Australia), a partner/sister company of Gencor. The technology addresses PEA's hydrophobic nature through water-dispersible delivery. Documented 1.75x absorption increase in published pharmacokinetic study.

2

PPAR-alpha activation

Levagen+® PEA activates PPAR-alpha nuclear receptors, modulating inflammation and lipid metabolism. Mechanism preserved with enhanced absorption.

3

Endocannabinoid-like signaling

PEA modulates the endocannabinoid system indirectly through 'entourage effects' — enhancing anandamide and other endogenous cannabinoid-like compounds. Mechanism contributes to pain, sleep, and inflammatory effects.

Clinical trials

1
Pain reduction at lower doses

Levagen+® clinical trials document pain reduction at 300-600 mg/day — substantially lower than typical PEA pain protocols. The dose advantage validates the bioavailability technology.

2
Sleep quality trials

Levagen+® clinical trials specifically target sleep quality applications with documented improvements. The sleep application is well-suited to the enhanced bioavailability format.

3
Cognitive and inflammation studies

Emerging clinical research targets cognitive function and inflammatory marker effects. Reflects expanding research investment in the bioavailable PEA format.

Side effects and drug interactions

Common Potential side effects

GENERALLY WELL-TOLERATED at standard doses.
Excellent safety profile inherited from PEA's long European medical food history.
Mild GI discomfort possible at higher doses.
No significant adverse events documented in clinical trial use.
Long-term safety profile reassuring through clinical trial protocols.
Pregnant women should consult healthcare providers.

Important Drug interactions

Generally minimal drug interactions documented.
Theoretical caution with anticoagulants — possible mild effects through inflammatory modulation.
No significant interactions with common pain medications — PEA is often used adjunctively.
Safe combinations with most cardiovascular, metabolic, and psychiatric medications.
Consult healthcare providers when combining with prescription medications for pain conditions.

More Anti-Inflammatory Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Anti-Inflammatory
Meriva® (Curcumin Phytosome — Indena)
Meriva® is a CURCUMIN PHYTOSOME® formulation developed by Indena (Italy) — using Indena's…
Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a PATENTED CURCUMIN EXTRACT developed by Verdure Sciences using SLCP™ (Solid…

Explore Other Ingredients

Sleep Health
Valerian Root
Valerian root is one of the most widely used herbal sleep aids in Western medicine, with a…
Sleep Health
Melatonin
Melatonin is a hormone produced by the pineal gland that regulates circadian rhythm and si…
Sleep Health
5-HTP (5-hydroxytryptophan)
5-Hydroxytryptophan (5-HTP) is a naturally occurring compound derived from L-tryptophan, s…

Frequently asked questions about Levagen+® (PEA — Palmitoylethanolamide — Gencor)

What is Levagen+® (PEA — Palmitoylethanolamide — Gencor)?

Levagen+® is the branded bioavailable palmitoylethanolamide (PEA) from Gencor (Austin, TX) — addressing the major issue with standard PEA: poor bioavailability of the hydrophobic compound.

What does Levagen+® (PEA — Palmitoylethanolamide — Gencor) do?

LipiSperse® is developed and owned by Pharmako Biotechnologies (Australia), a partner/sister company of Gencor. The technology addresses PEA's hydrophobic nature through water-dispersible delivery. Documented 1.75x absorption increase in published pharmacokinetic study. In clinical research, Levagen+® (PEA — Palmitoylethanolamide — Gencor) has been studied for enhanced bioavailability over standard pea, pain reduction at lower doses, sleep quality improvement.

Who should take Levagen+® (PEA — Palmitoylethanolamide — Gencor)?

Levagen+® (PEA — Palmitoylethanolamide — Gencor) may be most relevant for people interested in anti-inflammatory, cognitive, sleep. It has been clinically studied for enhanced bioavailability over standard pea, pain reduction at lower doses, sleep quality improvement. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Levagen+® (PEA — Palmitoylethanolamide — Gencor) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Levagen+® (PEA — Palmitoylethanolamide — Gencor)?

For anti-inflammatory and joint goals, Levagen+® (PEA — Palmitoylethanolamide — Gencor) is typically taken with meals — fat-containing food often improves absorption for fat-soluble compounds. Daily consistency matters more than precise timing for cumulative anti-inflammatory effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Levagen+® (PEA — Palmitoylethanolamide — Gencor) worth taking?

Levagen+® (PEA — Palmitoylethanolamide — Gencor) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Levagen+® (PEA — Palmitoylethanolamide — Gencor) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Levagen+® (PEA — Palmitoylethanolamide — Gencor)?

The clinically studied dose for Levagen+® (PEA — Palmitoylethanolamide — Gencor) is Standard dose: 300-600 mg/day Levagen+® — substantially lower than typical PEA protocols due to enhanced bioavailability. Sleep applications: 350 mg before bedtime. Pain applications: 300 mg twice daily. Long-term safety established through clinical trial use.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Levagen+® (PEA — Palmitoylethanolamide — Gencor) used for?

Levagen+® (PEA — Palmitoylethanolamide — Gencor) is studied for enhanced bioavailability over standard pea, pain reduction at lower doses, sleep quality improvement. Levagen+® combines Gencor's PEA with LipiSperse® dispersion technology from Pharmako Biotechnologies. A published pharmacokinetic study documented 1.